BRPI0512991A - uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto - Google Patents

uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto

Info

Publication number
BRPI0512991A
BRPI0512991A BRPI0512991-5A BRPI0512991A BRPI0512991A BR PI0512991 A BRPI0512991 A BR PI0512991A BR PI0512991 A BRPI0512991 A BR PI0512991A BR PI0512991 A BRPI0512991 A BR PI0512991A
Authority
BR
Brazil
Prior art keywords
contraception
female
pharmaceutically useful
progestin
oral administration
Prior art date
Application number
BRPI0512991-5A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512991A publication Critical patent/BRPI0512991A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

USO DE UMA PROGESTINA, KIT FARMACEUTICAMENTE úTIL ADAPTADO PARA A ADMINISTRAçãO ORAL DIARIA, E, MéTODO DE CONTRACEPçãO EM UMA FêMEA EM IDADE DE PARTO Um método de contracepção é fornecido que envolve a ministração em 21 a 27 dias consecutivos de uma progestina na ausência de um estrogênio ou outro composto esteróide, seguido por 1 a 7 dias sem uma quantidade eficaz de um agente ativo. Também é descrito um kit farmaceuticamente útil para facilitar a ministração deste regime.
BRPI0512991-5A 2004-07-07 2005-07-06 uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto BRPI0512991A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58604504P 2004-07-07 2004-07-07
PCT/US2005/023955 WO2006014476A1 (en) 2004-07-07 2005-07-06 Cyclic progestin regimens and kits

Publications (1)

Publication Number Publication Date
BRPI0512991A true BRPI0512991A (pt) 2008-04-22

Family

ID=35064935

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512991-5A BRPI0512991A (pt) 2004-07-07 2005-07-06 uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto

Country Status (14)

Country Link
US (3) US20060009428A1 (pt)
EP (1) EP1773344A1 (pt)
JP (2) JP5288796B2 (pt)
CN (2) CN104208067A (pt)
AR (1) AR049707A1 (pt)
AU (1) AU2005269938A1 (pt)
BR (1) BRPI0512991A (pt)
CA (1) CA2571377C (pt)
MX (1) MXPA06014579A (pt)
PA (1) PA8638601A1 (pt)
PE (1) PE20060378A1 (pt)
SV (1) SV2006002165A (pt)
TW (1) TW200603813A (pt)
WO (1) WO2006014476A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN104208067A (zh) 2004-07-07 2014-12-17 惠氏公司 周期性黄体酮方案及试剂盒
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
US20060246128A1 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compositions containing same
AR056328A1 (es) * 2005-04-28 2007-10-03 Wyeth Corp TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
DE602006007453D1 (de) * 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
CN103989687A (zh) * 2005-06-09 2014-08-20 惠氏公司 含有炔雌醇的tanaproget组合物
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
EA201070715A1 (ru) 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
CN102811730B (zh) * 2010-02-08 2014-07-09 杜涛 孕激素作为糖皮质激素增敏剂的使用
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
HUE065350T2 (hu) * 2015-06-23 2024-05-28 Laboratorios Leon Farma Sa Drospirenonalapú fogamzásgátló túlsúllyal érintett nõi beteg számára
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception
WO2024218800A1 (en) * 2023-04-21 2024-10-24 Akums Drugs And Pharmaceuticals Limited Vaginal drug delivery system of dydrogesterone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
EP0559240B1 (en) * 1987-09-24 2001-12-05 Jencap Research Limited Contraceptive packages containing oestrogen and progestin
WO1998004269A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
WO1999051214A2 (en) * 1998-04-07 1999-10-14 Akzo Nobel N.V. Progestogen-only contraceptive kit
MXPA01011287A (es) * 1999-05-04 2003-07-14 American Home Prod Derivados de ciclotiocarbamato como moduladores de receptor de progesterona.
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
EP1605949A2 (en) * 1999-08-31 2005-12-21 Schering Aktiengesellschaft Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AR040644A1 (es) * 2002-06-25 2005-04-13 Wyeth Corp Un moduladores del receptor de progesterona benzoxazina-2-tiona, una composicion farmaceutica, uso del compuesto para preparar un dedicamento para tratar una enfermedad neoplasica-hormona-dependiente y el uso de un compuesto benzoxazina-2-tiona, benzoxazina-2-ilideno cianamida o benzoxazina-2-iliden
CN104208067A (zh) 2004-07-07 2014-12-17 惠氏公司 周期性黄体酮方案及试剂盒
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
US20140094458A1 (en) 2014-04-03
WO2006014476A1 (en) 2006-02-09
JP2008505909A (ja) 2008-02-28
US8604027B2 (en) 2013-12-10
CA2571377A1 (en) 2006-02-09
CN104208067A (zh) 2014-12-17
PE20060378A1 (es) 2006-06-02
EP1773344A1 (en) 2007-04-18
JP5288796B2 (ja) 2013-09-11
AU2005269938A1 (en) 2006-02-09
US20100292198A1 (en) 2010-11-18
JP2013040181A (ja) 2013-02-28
PA8638601A1 (es) 2006-07-03
MXPA06014579A (es) 2007-03-01
AR049707A1 (es) 2006-08-30
SV2006002165A (es) 2006-05-09
CA2571377C (en) 2014-03-25
CN1980676A (zh) 2007-06-13
US20060009428A1 (en) 2006-01-12
TW200603813A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
TR200200406T2 (tr) Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
MA26843A1 (fr) NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE
HRP20050781B1 (hr) Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu
IL158903A0 (en) Use of sulodexide for the treatment of inflammatory bowel disease
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
CO5631449A2 (es) Nuevos esteres de etonogestrel
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
JP2009512658A5 (pt)
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
EE05259B1 (et) Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks
MX2009010320A (es) Regimen anticonceptivo oral.
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
DK1227814T3 (da) Hormonal sammensætning baseret på nomegestrolacetat og et östrogen samt anvendelse heraf
MX2024009584A (es) Metodos anticonceptivos con efectos de sangrado programado.
CY1111406T1 (el) Χρηση βαλερικης οιστραδιολης ή οιστραδιολης σε συνδυασμο με διενογεστη για την απο του στοματος θεραπεια της αιμορραγιας λογω δυσλειτουργιας της μητρας με τη μορφη απο του στοματος αντισυλληψης
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
EA200900829A1 (ru) Фармацевтический препарат для уменьшения эндометриоза
JP2005532336A5 (pt)
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: WYETH LLC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.